Informace o publikaci

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Autoři	KYLE RA. DURIE BG. RAJKUMAR SV. LANDGREN O. BLADE J. MERLINI G. KRÖGER N. EINSELE H. VESOLE DH. DIMOPOULOS M. SAN MIGUEL J. AVET-LOISEAU H. HÁJEK Roman CHEN WM. ANDERSON KC. LUDWIG H. SONNEVELD P. PAVLOVSKY S. PALUMBO A. RICHARDSON PG. BARLOGIE B. GREIPP P. VESCIO R. TURESSON I. WESTIN J. BOCCADORO M.
Rok publikování	2010
Druh	Článek v odborném periodiku
Časopis / Zdroj	Leukemia
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.1038/leu.2010.60
Obor	Onkologie a hematologie
Klíčová slova	Monoclonal gammopathy of undetermined significance; multiple myeloma
Popis	Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein <15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years.